Down 11% from Oct 9 to Oct 30 while the S&P 500 fell 3%.
ERAS's Quality Score fell 3 points on Fri, Oct 30, to 2. Closed more than 1.5% below its 21-day average (3 chart checks stopped).
Follow ERAS's trial news. Pro members can get an alert when Erasca files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | A $287M loss |
| Latest filing | 8-K, Oct 16 |
Wed Nov 18: AACR-NCI-EORTC (ENA) International…Industry event · date confirmed.
After its last 4 reports it closed -2.6% on average, higher 1 of 4 times.
The company says its cash lasts into H2 2028 (8-K, May 11).
Chief Legal Officer Ebun Garner sold 80,000 shares on Apr 1, under a planned sale. 2 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
ERAS is #42 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 42 |
Share count against a year before: ERAS +9.9%, COGT +49%, TNGX +36%, BBIO +2.8%.
Expected to report Wed Nov 11, after the close (in 9 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily driven by increases in expenses incurred in connection with clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs, including stock-based compensation expense.”
ERAS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Additional ERAS-0015 monotherapy and combination data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | +0.7% | +1.5% | -1.1% |
| May 11, 2026 | -2.1% | -0.6% | -1.6% |
| Mar 12, 2026 | +3.4% | -7.0% | +4.2% |
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ERAS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
ERAS scores 2 today, which Breakaway calls Below Average. It is #42 of 92 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 11% from Oct 9 to Oct 30 while the S&P 500 fell 3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ERAS scores 2 today, which Breakaway calls Below Average (0 to 5). That is #42 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ERAS's 2.
Expected to report Wed Nov 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ERAS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.